Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences

Publisher:
Elsevier
Publication Type:
Journal Article
Citation:
Value in Health, 2017, 20 (4), pp. 627 - 636
Issue Date:
2017-04
Full metadata record
Files in This Item:
Filename Description Size
Balancing the Optimal and the Feasible A Practical Guide for.pdfPublished Version369.48 kB
Adobe PDF
© 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Objectives: The aim of this article was to provide practical guidance in setting up patient registries to facilitate real-world data collection for health care decision making. Methods: This guidance was based on our experiences and involvement in setting up patient registries in oncology in the Netherlands. All aspects were structured according to 1) mission and goals ("the Why"), 2) stakeholders and funding ("the Who"), 3) type and content ("the What"), and 4) identification and recruitment of patients, data handling, and pharmacovigilance ("the How"). Results: The mission of most patient registries is improving patient health by improving the quality of patient care; monitoring and evaluating patient care is often the primary goal ("the Why"). It is important to align the objectives of the registry and agree on a clear and functional governance structure with all stakeholders ("the Who"). There is often a trade off between reliability, validity, and specificity of data elements and feasibility of data collection ("the What"). Patient privacy should be carefully protected, and address (inter-)national and local regulations. Patient registries can reveal unique safety information, but it can be challenging to comply with pharmacovigilance guidelines ("the How"). Conclusions: It is crucial to set up an efficient patient registry that serves its aims by collecting the right data of the right patient in the right way. It can be expected that patient registries will become the new standard alongside randomized controlled trials due to their unique value.
Please use this identifier to cite or link to this item: